1047 Patient Study Demonstrates Restoration of Sensation in Peripheral Neuropathy Which Could Reduce Risk of Amputations
Anodyne Therapy announced the publication of a sixth peer-reviewed clinical study that demonstrates restoration of sensation in the feet of patients with peripheral neuropathy.
Tampa, FL (PRWEB) March 31, 2005
Anodyne Therapy, LLC today announced the publication of a sixth peer-reviewed clinical study demonstrating restoration of sensation in the feet of patients with peripheral neuropathy. The purpose of the study was to measure improvements in patientsÂ’ ability to feel a standardized 10 gram Semmes-Weinstein Monofilament (SWM) test - the test deemed by Medicare in a 2001 Decision Memorandum to be the best measure of risk for diabetic ulcers amputations. The study appears in the March/April 2005 issue of The Journal of the American Podiatric Medical Association.
Previous studies have shown that sensory impairments due to peripheral neuropathy present a significant independent risk for wounds that could not be adequately addressed because of the lack of a treatment intervention for the underlying sensory loss. Prior to receiving Anodyne treatments, the patients with peripheral neuropathy in this study had sensory loss at 7.9 sites of 10 sites tested based on the standardized SWM test. Any patients with more than 2 sites insensate to the SWM are deemed to have “Loss of Protective Sensation” or LOPS, a serious illness of the foot requiring special shoes and more frequent foot exams to prevent ulcers and amputations. After treatments were administered using Anodyne Therapy in a clinical setting, the patients had an improvement in sensation to an average of only 2.3 sites with sensory loss – a mean improvement of 5.6 sites per patient. In fact, of the 1033 patients who had LOPS, 580 (56%) regained protective sensation.
“We have had several smaller studies published, but having a study published with over a thousand patients diagnosed with both diabetic and non-diabetic neuropathies, demonstrates how significant the clinical effect of Anodyne Therapy is on this debilitating condition,” said Craig Turtzo, CEO. “It is very rewarding to give hope to people with peripheral neuropathy, who, prior to Anodyne, did not have access to treatment options that could restore protective sensation – thus potentially preventing ulcers and amputations. The medical costs normally associated with peripheral neuropathy have been estimated to exceed $37 billion per year among people with diabetes alone.”
Anodyne Therapy treatments are currently available nationwide at more than 2800 outpatient therapy facilities, hospitals, nursing homes, physician offices and home health agencies to improve functional outcomes for patients suffering from peripheral neuropathy, chronic pain and a broad range of other health problems. Products are also available for convenient home use.
For more information, visit www. anodynetherapy. com.
# # #
